October 10, 2006

Announcement of the Release of Automated Plasma Preprocessing System for MS Analyses

Listed Company Name: Precision System Science Co., Ltd.
（Code Number 7707）

Address: 88 Kamihongo, Matsudo-shi, Chiba, Japan

Contact: Jun Akimoto, Director & Executive Officer

Telephone: 047-303-4800

URL http://www.pss.co.jp/

Precision System Science Co., Ltd （Headquarters: Matsudo-shi, Chiba; President: Hideji TAJIMA, hereinafter referred to as PSS） is announcing the completion of the development of an automated plasma preprocessing system for MS analyses which PSS has been making collaborative efforts in developing with Medical ProteoScope Co., Ltd. (Headquarters: Shinjuku-ku, Tokyo; President: Tetsuhito MATSUYAMA, herein after referred to as MPS)[*1] since January, 2006, and the commencement of sales of the system upon receiving orders under the agreement with MPS.

"MS" stands for "Mass Spectrometry" and indicates a mass analytical technique[*2].

Currently, MS analyses of human clinical samples are actively conducted in searches of new bio-markers of unique diseases, side effects, or drug development target molecules and the studies of effectiveness of therapeutic products. Conducting MS analyses for these studies is believed to lead to development of diagnostic or pharmaceutical products and the eventual realization of providing personalized medical services.

This co-development effort has resulted in the fusion of PSS' automation system technology which PSS has been cultivating up to now and MPS' clinical proteome analyzing technology and preprocessing technology through the use of MS; as the result of this fusion of technologies, an innovative, automated system that would improve the productivity and reproducibility of cumbersome sample (such as plasma) preprocessing for MS analyses has successfully been realized.

The co-developed system has new technologies (including one patent-pending invention) installed and is expected to be put into practical use not only for preprocessing for MS analyses but as an automated sample preparation system in various proteomics researches that handle protein samples.

“ProScope” Exterior

The standard model of ProScope (the trade name), scheduled to be manufactured and sold upon order acceptance, can handle up to 8 samples at a time. It automatically processes a sequence of operations from the removal of major proteins to the concentration/buffer exchanges by ultra filtration in a seamless manner. The forecasted sales price of the standard model is 8,000,000 yen and the forecasted number of units to be sold is twenty.

It is difficult, however, at this point, to work out accurate sales forecasts of this instrument. For this reason, we intend to announce adjustments to the operating performance forecasts immediately, once it becomes evident that the sales of the instrument will have an impact on the account closing for this fiscal year.

<References>

*1 Medical ProteoScope Co., Ltd.

Medical ProteoScope Co., Ltd. (MPS) is Bio Venture company which has a unique, original and inetgrated clinical proteome technology. MPS Integrated Technology discover new biomarkers (proteins) for drug responses (efficacy, side effects etc) with just adding one more plasma or serum sample in your clinical development.

Company Name	Medical ProteoScope Co., Ltd.
Location	ShinjukuSumitomo Bldg. 17F, 2-6-1, Nishi-Shinjuku, Shinjuku-ku, Tokyo 163-0217
Established	November, 2002
Total stockholders' equity	1,368 million yen (as of September, 2006)
Representative	Tetsuhito MATSUYAMA, President
Business Descriptions	Development of pharmaceutical products based on clinical proteomics

*2 Mass Spectrometry

Mass spectrometry is an analytical technique to ionize samples by laser radiation or ionization spraying and separate and detect ions in proportion to the mass and the electrical charge; the technique is utilized for the analyses of existential quantity of protein, molecular structures, etc. that exist in synthetic compounds or living orgasms.

For instance, in the case of a person developing a disease such as a cancer or a life-style related disease, the protein that expresses and varies in a disease-specific manner could be extracted from an organ or blood, depending on the progress of a disease using a highly sensitive analytical technique such as mass spectrometry. The protein, then, could be used as a bio-marker for the monitoring of incidences of certain diseases, early detections, progress and prognostic monitoring of diseases, malignancy of tumors, diagnosis of metastasis, and so forth. At present, detection and identification researches of disease-specific molecules using mass spectrometers are actively conducted at various research institutions including cancer centers.